Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Table 1 Comparative safety of IFX SC and VDZ during a 1-year period in patients with Crohn’s disease

Outcome	Group	Events	Total	Proportion (95% CI)	Heterogeneity (I²)
AE	IFX SC	40	53	0.76 (0.58-0.88)	0%
AE	VDZ	788	985	0.78 (0.59-0.90)	98%
SAE	IFX SC	5	53	0.09 (0.04-0.21)	0%
SAE	VDZ	198	985	0.16 (0.08-0.30)	93%
Infection	IFX SC	20	53	0.38 (0.26-0.51)	0%
Infection	VDZ	73	427	0.17 (0.14-0.21)	24%
Serious infection	IFX SC	2	53	0.04 (0.01-0.14)	0%
Serious infection	VDZ	44	985	0.04 (0.02-0.08)	67%
Discontinuation due to AEs	IFX SC	2	53	0.04 (0.01-0.14)	0%
Discontinuation due to AEs	VDZ	89	985	0.07 (0.03-0.15)	84%

AE Adverse event, CI Confidence interval, IFX Infliximab, SAE Serious adverse event, SC Subcutaneous, VDZ Vedolizumab

ISSN: 1471-230X